# ImmunityBio, Inc. Common Stock (IBRX) — Stock CV

ImmunityBio, Inc. is a $11.2B healthcare company. Revenue grew 192.9% over the last year, and it currently loses money.

> ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases.

## Identity

- **Ticker**: IBRX
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: SAN DIEGO, CA
- **Employees**: 691
- **Website**: https://www.immunitybio.com
- **Market cap**: $11.2B
- **Last price**: $10.57
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $166M
- **Net income**: -$992M
- **Free cash flow**: -$288M
- **Revenue growth (YoY)**: 192.9%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 20 |
| Growth | 25 |
| Profitability | 0 |
| Health | 28 |
| Quality | 15 |
| Moat | 0 |

## Qualifications (beginner checklist) — 4 of 9 passed

- [x] Revenue growing — +192.9% YoY
- [ ] Profitable — -$992M TTM
- [x] Profit growing — +15.0% YoY
- [ ] Generates cash — -$288M TTM
- [x] Debt under control — current ratio 5.72
- [x] Established company — $11.2B market cap
- [ ] Not printing shares — +136.3% shares over ~5y
- [ ] Proven track record — 0/10 profitable years
- [ ] Financially stable — Altman Z -6.1 — distress

## Experience (career milestones)

- **2020** — A product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine

## Strengths

- High gross margin (99.3%)
- Revenue growing 192.9% year over year

## Watch-outs

- Not profitable — 598.6% net margin
- Negative free cash flow (-$288.0M)
- Altman Z-Score -6.14 — elevated financial-distress risk
- Thin interest coverage (-1.4×)
- Loss-making in 10 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $934K | -$347M | -$308M |
| FY2022 | $240K | -$417M | -$416M |
| FY2023 | $622K | -$583M | -$397M |
| FY2024 | $14.7M | -$414M | -$398M |
| FY2025 | $113M | -$351M | -$309M |

---

Source: https://stockcv.com/IBRX — derived from company filings; may be delayed or incomplete. Information, not investment advice.